Guggenheim Capital LLC Arvinas, Inc. Transaction History

Guggenheim Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$26.15 - $37.26 $39,329 - $56,039	1,504 Added 23.52%	7,898 $215,000
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $40,490 - $71,378	1,247 Added 24.23%	6,394 $218,000
Q3 2022 Nov 14, 2022	SELL	$41.87 - $57.99 $1,591 - $2,203	-38 Reduced 0.73%	5,147 $229,000
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $936 - $1,930	-26 Reduced 0.5%	5,185 $218,000
Q1 2022 May 16, 2022	BUY	$60.27 - $81.57 $52,615 - $71,210	873 Added 20.12%	5,211 $351,000
Q4 2021 Feb 14, 2022	BUY	$65.85 - $96.21 $115,039 - $168,078	1,747 Added 67.43%	4,338 $356,000
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $189,661 - $279,491	2,591 New	2,591 $213,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $997M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Guggenheim Capital LLC with notifications on news.